Desensitization for renal transplantation: Depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks

Transplant International

Volumn 24, Issue 1, 2011, Pages 21-29

  Rogers, Natasha M ^a,b,c   Eng, Hooi S ^d   Yu, Raymond ^c   Kireta, Svjetlana ^b   Tsiopelas, Eleni ^d   Bennett, Greg D ^d   Brook, Nicholas R ^a   Gillis, David ^e   Russ, Graeme R ^a,b,c   Coates, P Toby ^a,b,c,d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^e INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

antibodies; desensitization; kidney transplant

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TETANUS ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA MATCHING; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OXALOSIS; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SEPTICEMIA; SINGLE DRUG DOSE; SYSTEMATIC DESENSITIZATION;

ADULT; AGED; ANTIBODIES; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; RECOMBINANT FUSION PROTEINS; STREPTOCOCCUS PNEUMONIAE; TACROLIMUS; TETANUS; TISSUE DONORS;

EID: 78650029941     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01138.x     Document Type: Article

References (42)

1. Morales-Buenrostro L, Terasaki P, Marino-Vazquez L, Lee J, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 111.
2. El Aggan H, Helmy M, Mahmoud A,. Anti-human leukocyte antigen (HLA) antibodies in non-transfused, non-transplanted patients with chronic hepatitis C. Gastroenterology 2003; 124: A740.
3. El Aggan H, Sidkey F, Al Gezery D, Ghoneim E,. Circulating anti-HLA antibodies in patients with chronic hepatitis C: relation to disease activity. Egypt J Immunol 2004; 11: 71.
4. Cervelli C, Fontecchio G, Fioroni M, et al. Interferon-α therapy and anti-human leutkocyte antigen antibodies in hepatitis C virus-positive patient: case report. Transplant Proc 2007; 39: 2040.
5. Patel R, PI T,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
6. Bittencourt M, Rebibou J, Saint-Hillier Y, et al. Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Nephrol Dial Transplant 1998; 13: 2059.
7. Eng H, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335.
8. Mahoney R, Taranto S, Edwards E,. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63: 324.
9. ANZDATA. The Queen Elizabeth Hospital, South Australia, Australia.
10. U.S. Renal Data System U, Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2008.
11. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
12. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
13. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531.
14. Thielke J, DeChristopher PJ, Sankary H, Oberholzer J, Testa G,. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc 2005; 37: 643.
15. Maloney D, Grillo-Lopez A, White C,. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188.
16. Eng H, Bennet G, Bardy P, Coghlan P, Russ G, Coates P,. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009; 70: 595.
17. Grim S, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628.
18. ANZDATA Registry Report, Appendix I-II. Australia and New Zealand Dialysis and Transplant Registry 2008.
19. Campbell S, McDonald S, Livingston B,. Ch 7: Transplant waiting list. ANZDATA, 2008 Report. South Australia, Australia: The Queen Elizabeth Hospital, 2008.
20. Kamar N, Milioto O, Puissant-lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
21. Tsepepas D, Aull M, Dadhnia D, Kapur S,. Risk of infection in kidney-transplant recipients treated with rituximab. Am J Transplant 2008; 9 (suppl 2): 564. Abstract 1452).
22. Piro L, White C, Grillo-Lopez A,. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655.
23. DiLillo D, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 361.
24. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics of B cell immunotherapy. J Immunol 2005; 174: 817.
25. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, MD P,. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55.
26. Jordan S, Vo A, Bunnapradist S, Tyan D,. IVIG inhibits cross-match (CMX) positivity and allows successful transplantation in living donor and cadaveric transplant recipients (abstract). Am J Transplant 2002; 3: 867.
27. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
28. Glotz D, Antoine C, Julia P, et al. Desensitisation and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
29. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M,. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
30. Higgins R, Bevan D, Carey B, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before transplantation. Lancet 1996; 348: 1208.
31. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitised cross-match positive cadaveric allograft recipients. Transplantation 2005; 79: 696.
32. Ferrari-Lacraz S, Aubert V, Buhler L, et al. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation. Swiss Med Wkly 2006; 136: 696.
33. Stegall M, Gloor J, Winters J, Moore S, DeGoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific antibody. Am J Transplant 2006; 6: 346.
34. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
35. Gloor J, DeGoey S, Pineda A, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017.
36. Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
37. Gloor J, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
38. Salama A, Delikouras A, Pusey C, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
39. Stegall M, Gloor J,. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8.
40. Zachary A, Kopchaliiska D, KJackson A, Lefell M,. Immunogenetics and immunology in transplantation. Immunol Res 2010; Published online January 2010.
41. Zachary A, Lefell M,. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591.
42. Locke J, Zachary A, Warren D, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9: 2136.